JP2023513592A - ポリペプチド及びそれらの使用（関連出願の相互参照） - Google Patents

ポリペプチド及びそれらの使用（関連出願の相互参照） Download PDF

Info

Publication number
JP2023513592A
JP2023513592A JP2022549070A JP2022549070A JP2023513592A JP 2023513592 A JP2023513592 A JP 2023513592A JP 2022549070 A JP2022549070 A JP 2022549070A JP 2022549070 A JP2022549070 A JP 2022549070A JP 2023513592 A JP2023513592 A JP 2023513592A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
nanoparticle
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513592A5 (https=
Inventor
キング，ニール，ピー．
ウォーキー，カール
ワン，ジン，ヤン
フィアラ，ブルック
ヴィ―スラー，デイヴィット
ウォールズ，アレクサンドラ，シー．
ナッターマン，ウーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2023513592A publication Critical patent/JP2023513592A/ja
Publication of JP2023513592A5 publication Critical patent/JP2023513592A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
JP2022549070A 2020-02-14 2021-02-12 ポリペプチド及びそれらの使用（関連出願の相互参照） Pending JP2023513592A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US62/977,036 2020-02-14
PCT/US2021/017856 WO2021163481A1 (en) 2020-02-14 2021-02-12 Polypeptides and their use

Publications (2)

Publication Number Publication Date
JP2023513592A true JP2023513592A (ja) 2023-03-31
JP2023513592A5 JP2023513592A5 (https=) 2024-02-19

Family

ID=77292738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549070A Pending JP2023513592A (ja) 2020-02-14 2021-02-12 ポリペプチド及びそれらの使用（関連出願の相互参照）

Country Status (10)

Country Link
US (1) US20230075095A1 (https=)
EP (1) EP4103586A4 (https=)
JP (1) JP2023513592A (https=)
KR (1) KR20220142471A (https=)
AU (1) AU2021220958A1 (https=)
BR (1) BR112022016197A2 (https=)
CL (2) CL2022002215A1 (https=)
CO (1) CO2022011395A2 (https=)
PE (1) PE20230486A1 (https=)
WO (1) WO2021163481A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
WO2023196871A2 (en) * 2022-04-07 2023-10-12 University Of Washington Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery
EP4704892A2 (en) 2023-05-01 2026-03-11 University of Washington Pre-fusion-stabilized cmv gb protein nanostructures
WO2025059498A2 (en) * 2023-09-15 2025-03-20 Icosavax, Inc. Viral proteins and nanostructures and uses thereof
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025207938A1 (en) * 2024-03-29 2025-10-02 University Of Washington Nucleic acid vaccines against coccidioidomycosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016199898A1 (ja) * 2015-06-10 2016-12-15 公立大学法人 富山県立大学 活性型変異酵素の製造方法および新規活性型変異酵素、並びに可溶性化変異タンパク質の製造方法
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123763A1 (en) * 2004-06-16 2005-12-29 Dsm Ip Assets B.V. Production of polypeptides by improved secretion
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
JP6957039B2 (ja) * 2016-09-06 2021-11-02 学校法人慶應義塾 融合タンパク質、構造体、捕集剤、捕集する方法、ｄｎａ、及びベクター
US11866699B2 (en) * 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
HUE073526T2 (hu) * 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
WO2019241483A1 (en) * 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
FR3083804B1 (fr) * 2018-07-13 2022-08-12 Institut Nat Des Sciences Appliquees De Toulouse Micro-organismes et procede pour la production d'acide glycolique a partir de pentoses et d'hexoses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016199898A1 (ja) * 2015-06-10 2016-12-15 公立大学法人 富山県立大学 活性型変異酵素の製造方法および新規活性型変異酵素、並びに可溶性化変異タンパク質の製造方法
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Also Published As

Publication number Publication date
BR112022016197A2 (pt) 2022-10-25
AU2021220958A1 (en) 2022-09-01
CL2025002147A1 (es) 2026-03-06
US20230075095A1 (en) 2023-03-09
CO2022011395A2 (es) 2023-01-16
WO2021163481A1 (en) 2021-08-19
CL2022002215A1 (es) 2023-05-05
EP4103586A1 (en) 2022-12-21
KR20220142471A (ko) 2022-10-21
EP4103586A4 (en) 2024-05-15
PE20230486A1 (es) 2023-03-21

Similar Documents

Publication Publication Date Title
JP2023513592A (ja) ポリペプチド及びそれらの使用（関連出願の相互参照）
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
JP2021074020A (ja) 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
US11759514B2 (en) Stabilized pre-fusion RSV F proteins
JP7385680B2 (ja) 変異型ｒｓｖ ｆタンパク質及びその利用
CA3117275A1 (en) Stabilized pre-fusion rsv f proteins
Zhang et al. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
EP4448802A1 (en) Stabilized pre-fusion hmpv fusion proteins
CN111655284A (zh) 流感病毒疫苗及其用途
WO2025241210A9 (zh) RSV pre-F突变体及其生产方法和用途
AU2020367242B2 (en) Influenza virus vaccines and uses thereof
US20260117202A1 (en) Mutant of rsv f protein
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
WO2022177990A2 (en) Modified sars-cov-2 spike polypeptides and nanoparticles thereof
US11078240B2 (en) Covalently fused viral coat proteins for the display of target molecules
US10377798B2 (en) Recombinant respiratory syncytial virus G protein fragments
JP2023002492A (ja) 変異型ｒｓｖ ｆタンパク質を含む医薬組成物
US9771395B2 (en) Enhanced influenza hemagglutinin binders
Liu et al. Effect and mechanism of C-terminal cysteine on the properties of HEV p222 protein
Zhang et al. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent
US11191825B2 (en) Compositions and methods for vaccination against influenza
HK40111374A (zh) Rsv pre-f突变体及其生产方法和用途
HK40111374B (zh) Rsv pre-f突变体及其生产方法和用途
WO2023061993A1 (en) Polypeptides
RU2495938C2 (ru) СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО АНТИГЕНА G2 ХАНТАВИРУСА ДОБРАВА В КЛЕТКАХ E. coli

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417